ERX1000

DRUG2 trials

Sponsors

ERX Pharmaceuticals

Conditions

ObesityObesity & Overweight

Phase 1

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

CompletedNCT04890873

ERX PharmaceuticalsObesity

Start: 2019-10-17End: 2023-07-03Updated: 2023-10-24

Phase 2

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

RecruitingNCT07570758

ERX PharmaceuticalsObesity & Overweight

Start: 2026-05-28End: 2027-05-01Target: 80Updated: 2026-06-22